A similar study by Schoenfeld et al. [65] on 1586 lung adenocarcinoma patients with paired PD-L1 and targeted-NGS data not only confirmed the association of the EGFR and STK11 mutations with PD-L1 negativity but also showed that the KRAS, TP53, and MET mutations were significantly associated with high PD-L1 expression. This evidence concerns the gene KRAS and lung adenocarcinoma.